Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

HoneyButter Sep. 22 at 2:25 PM

$VKTX the real play here is as an acquisition target. $MRK or $PFE are the most likely. For a mere $7-10 billion they get a drug that has best in class weight loss, orally available, well tolerated, weight loss is immediate out the gate, and transitions to monthly maintenance. Whomever acquires this company is immediately in the game.

2 · Reply

PAHANA Sep. 22 at 2:16 PM

$PFE Revenue is down 2% YoY while $NVO revenue is up 6% YoY yeah stupid

0 · Reply

focafoca99 Sep. 22 at 2:15 PM

$PFE opens webcast registration for its November 3 analyst call. https://www.rapidticker.com/news/pfe-pfizer-invites-public-to-view-f60b9c

0 · Reply

La_Parka3 Sep. 22 at 2:01 PM

$MRNA $PFE Again, don’t say I didn’t warn the shorts that the Illuminati, the Freemasons, the Rothschilds, the World Economic Forum, and the New World Order have an agenda, and they have the longs’ backs. 🤣🤣🤣 I posted this a week ago. More pain to come for the shorts. And a big thank you to all the groups above for taking such good care of my investment.

0 · Reply

mrtallman Sep. 22 at 1:44 PM

$PFE ticker FLNA will double today. Drug study resumed

0 · Reply

DefenseMania Sep. 22 at 1:15 PM

$AMGN $LLY $PFE $ABBV https://finance.yahoo.com/healthcare/articles/amgen-announces-positive-topline-phase-130000414.html

0 · Reply

biolover Sep. 22 at 1:12 PM

$VKTX vs $PFE

0 · Reply

UnKnownWall Sep. 22 at 12:57 PM

$VKTX $VKTX maintenance trial, 98% kept their loss-weight on every other week, 90% kept their loss-weight on monthly dose !!! $LLY $NVO $PFE $MRK and big pharms now time to offer your price. Expect the news of offering and tomorrow BL Forum. Brian has to say nice words

0 · Reply

TopShelfStock Sep. 22 at 12:51 PM

$NVAX $NVAX The opening bell is ringing here at 8:30 AM Central Time and the setup is looking PHENOMENAL. 🔔🔥 Don't lose sight of the big picture today. Novavax is completely evolving into a high-margin biotech powerhouse. The chart is screaming bullish, holding beautifully above the 20-day and 50-day EMAs on surging volume. 📈 Smart money is laser-focused on two massive, game-changing fundamental catalysts right around the corner: The Pfizer Factor: $PFE has locked in their disease target. The second clinical trials are officially initiated, a massive $70M cash milestone is unlocked. 💰 The Oncology Revolution: Preclinical data drop expected in the coming quarters showing Matrix-M turning "cold" tumors "hot" to shrink them. 🔬 The platform pivot is real, the revenue runway is secured into the 2030s, and the tape is ready to squeeze.Let's smash through resistance today, bulls. Hold tight! 💎🙌🚀 #OpeningBell #BioTech #Breakout

1 · Reply

biolover Sep. 22 at 12:43 PM

$VKTX That is $PFE $10 B drug performance at wk 28 wt loss (12% despite wkly doses and flattening of curve vs 22% at $VKTX 33 wks ) and look at vomit rate in the monthly maintenance in vesper 1 after wk 28

0 · Reply

Pfizer Transcript: U.S. All Stars Conference

Sep 21, 2026, 5:41 PM EDT - 16 hours ago

Pharmaceutical Companies Push Trump Administration to Protect China Deals

LLY MRK PFE

Sep 15, 2026, 10:00 AM EDT - 7 days ago

Market Cap	157.65B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	9.07
Forward PE	9.29
Profit Margin	12.42%
Debt to Equity Ratio	0.74

Volume	28,776,600
Avg Vol	37,498,578
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	52%
Beta	0.34
Analysts	Sell
Price Target	$28.92